Gland Pharma IPO Closed
Already have an account? Apply now
About Gland Pharma
Gland Pharma is launching a Rs 6000 crore IPO which comprises a fresh issue of about Rs 1250 crores and an offer for sale from the existing shareholders for the balance. As per the prospectus, Gland Pharma is one of the fastest-growing generic injectables-focused companies by revenue in the United States from 2014 to 2019. The company sells products primarily under a business to business (“B2B”) model in over 60 countries as of March 31, 2020, including the United States, Europe, Canada, Australia, India, and the Rest of the world.
Check out the total revenue from operations, EBITDA, and restated profit (in Rs. million) and the EPS (in Rs.):
| Particulars | Fiscal 2018 | Fiscal 2019 | Fiscal 2020 |
|---|---|---|---|
| Revenue from operations | 16,228.93 | 20,442.03 | 26,332.40 |
| EBITDA | 5,840.75 | 7,920.67 | 10,946.35 |
| Restated profit for the year | 3,210.51 | 4,518.56 | 7,728.58 |
| Earnings Per Share (in Rs.) | 20.72 | 29.16 | 49.88 |
How do I apply for the Gland Pharma IPO?
You can apply for the Gland Pharma IPO using any supported UPI app by following two steps:
- Enter your bid on Console
- Accept UPI mandate on your phone
On acceptance of the mandate, the bid amount will get blocked in your bank account. Click here to learn more.